This antibody recognizes the anti-apoptotic protein BCL2, which is useful in distinguishing between neoplastic and reactive follicular lymphoma (BCL2-negative). It indcates cancers of breast, prostate, ovary, endometrium and colon. A recently identified protein,designated Bax p21 (Bcl-associated X protein ), has extensive amino acid homology with Bcl-2. Overexpression of Bax accelerates apoptotic death induced by cytokine deprivation and it counters the death repressor activty of Bcl-2.

[1] Hata AN, Engelman JA and Faber AC (2015): The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 5(5):475-87.
[2] Anderson MA, Huang D and Roberts A (2014): Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 51(3):219-27.
[3] Vogler M (2014): Targeting BCL2-Proteins for the Treatment of Solid Tumours. Adv Med. 2014:943648.